Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1130598 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $0.48Day −6.10%Mkt cap $7MP/E (FY) 0.6×1Y −69.1%Off 52W high −85.3%Vol (1Y) 129.7%
Daily closing price, split-adjusted to the current basis; 2.3y shown of 579 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.6% of sh out |
| Days to cover3.8d |
| 13F net flow (QoQ)−1.26% |
| Top-10 13F concentration96.3% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)0.6× |
| Sales (TTM)$2.9M |
| Earnings (TTM)-$19.4M |
| Net margin328.7% |
| Sales growth 3Y131.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−57.4% |
| 1Y−69.1% |
| Since incept. (ann.)−80.5% |
Total return through 2026-07-29 · series begins 2024-04-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)129.7% |
| Ann. volatility (3Y)150.1% |
| Sharpe (1Y)−0.27 |
| Sharpe (3Y)−0.49 |
| Max drawdown (1Y)−84.6% |
| Max drawdown (3Y)−97.8% |
| Beta (3Y vs SPY)0.59 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 730,000 | $1M | 4.82% | +0.0% |
| Ikarian Capital, LLC | 678,142 | $1M | 4.48% | +0.0% |
| ORBIMED ADVISORS LLC | 605,531 | $1M | 4.00% | +0.0% |
| Squadron Capital Management LLC | 511,714 | $936,437 | 3.38% | −28.3% |
| Dauntless Investment Group, LLC | 416,998 | $763,106 | 2.75% | new |
| BOOTHBAY FUND MANAGEMENT, LLC | 194,536 | $356,001 | 1.28% | +0.0% |
| ADAR1 Capital Management, LLC | 154,098 | $281,999 | 1.02% | −0.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 77,103 | $141,100 | 0.51% | +25.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.53 | −125.4% | — | — |
| 2025-09-30 | 2025-11-13 | −$0.34 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.11 | — | $2.7M | +4694.7% |
| 2025-03-31 | 2025-05-15 | $2.09 | — | $57,000 | +1.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
